why choose us

First received: February 06, 2023

Clinical Trial: Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Waldenstrom Macroglobulinemia

Study Type: INTERVENTIONAL


Official Title: A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström Macroglobulinemia

Brief Summary: This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM).The names of the study drugs involved in this study are:Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor)Venetoclax (a BCL2 inhibitor)

Read more